Robin Carr

CEO at MyricxBio

Speaker

Robin initially trained as a medicinal chemist. After several of his early programs failed to reach the clinic, he became fascinated by novel drug discovery technologies and design approaches that could potentially overcome some of the limitations of current drug discovery methods. This interest led Robin to work across both pharmaceutical and biotech sectors and explore a range of emerging technologies, such as DNA-encoded libraries, covalent drug discovery, fragment-based drug discovery, and, more recently, novel antibody-drug conjugate (ADC) payloads. Over the last 35 years, Robin has worked on a wide range of projects, a smallish number of which have progressed through clinical studies. Robin is currently the CEO of Myricx Bio, a London-based academic spinout. The company pivoted from small molecule oncology to ADCs and raised a $117 million Series A round in the summer of 2024 to advance proprietary NMTi ADCs into the clinic.